CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Michael Davidson

Chief Executive Officer, NewAmsterdam Pharma Company N.V.

Search every verified Michael Davidson interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Michael Davidson, Chief Executive Officer of NewAmsterdam Pharma, appeared on a podcast in September 2026 where he discussed his clinical work as a cardiologist and lipidologist, as well as his views on prevention and lipid-lowering therapies. He described his focus on primary prevention, explaining that he advocates for intervening early to prevent plaque formation rather than waiting for significant buildup or cardiovascular events. He also discussed the concept of primordial prevention, noting the challenge of persuading younger patients to begin statin therapy. During the conversation, Davidson discussed the potential of obicetrapib, a drug developed by his company, suggesting that based on available data it could become a next-line treatment, possibly in combination with ezetimibe, to manage lipid levels for a large proportion of patients. He also referenced genetic studies, including the Bronx aging study, which he said showed that CETP loss-of-function variants were common in long-lived individuals and that such variants appeared to mitigate Alzheimer's disease risk in those with APOE4.

Recent appearances

  • 407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and more

    September 13, 2026 · 📺 Peter Attia MD

    Michael Davidson is a world-renowned cardiologist, lipidologist, and the founding CEO of NewAmsterdam Pharma. He begins this episode by sharing how his family history shaped his interest in lipidology and primary prevention. He explains why prevention should focus on causal drivers of disease rather than near-term risk and examines the causal relationship between LDL and atherosclerotic cardiovascular disease. 0:00:00 - Intro 0:00:11 - Michael’s path to lipidology, and his passion for primary prevention 0:07:54 - Reframing prevention around causal drivers rather than time horizon 0:14:11 - Wh…

    Watch on YouTube ↗

  • From Doctor to Drug Developer: NewAmsterdam Pharma’s CEO on Transforming Patient Care

    October 06, 2025 · 📺 Kinara

    In this episode of the Kinara podcast, NewAmsterdam Pharma CEO and founder Dr. Michael Davidson sits down with Kinara co-editor Chase Feiger to discuss the importance of preventive care in cardiology. He also shares how he balances his work as a life-sciences entrepreneur with his ongoing care of patients in need.

    Watch on YouTube ↗

  • $NAMS Obicetrapib: ROSE2 Trial Results - Michael Davidson, MD - NewAmsterdam

    October 31, 2023 · 📺 Dan-The-Investor-inventor-truther

    In a conversation with cardiologytalk.com, Dr. Michael H. Davidson, MD, FACC, a professor of medicine and director of the Lipid Clinic at the University of Chicago, as well as the Chief Executive Officer of New Amsterdam Pharma, shared insights on the ROSE2 trial. He discussed the trial's findings and its potential impact on cardiovascular disease. Dr. Davidson stated, "We presented at the National Lipid Association as a late breaker, and then it was simultaneously published in the Journal of Clinical Lipidology." Regarding the effectiveness of the combination of Obacetrapib and Ezetimibe in…

    Watch on YouTube ↗

  • NewAmsterdam Pharma: Clinical stage biopharmaceutical company focusing on metabolic diseases

    February 13, 2023 · 📺 LilaMax Media

    Jane King interviews Michael Davidson, M.D., CEO, NewAmsterdam Pharma (Nasdaq: NAMS) https://www.newamsterdampharma.com Innovators with Jane King profiles tech companies and thought leaders in the space. We're showing you a glimpse of the future. NewAmsterdam (Nasdaq:NAMS) is a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferr…

    Watch on YouTube ↗

  • NewAmsterdam Pharma (NASDAQ:NAMS): Transformational therapies for patients with metabolic diseases

    November 26, 2022 · 📺 LilaMax Media

    Jane King interviews Michael Davidson, M.D., CEO, NewAmsterdam Pharma; and Lina Gugucheva, Chief Business Officer. https://www.newamsterdampharma.com Innovators with Jane King profiles tech companies and thought leaders in the space. We're showing you a glimpse of the future. (FROM COMPANY WEBSITE) Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer’s disease. Our mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not…

    Watch on YouTube ↗

  • Tales from the Trenches: Dr. Michael Davidson, founder, Corvidia Therapeutics

    September 24, 2020 · 📺 MATTER

    In a conversation moderated by Illinois Ventures CEO Nancy Sullivan, join hear how Dr. Michael Davidson balances being a physician and serial entrepreneur, what he has learned from scaling and selling two large pharmaceutical companies and his plans for his latest venture: New Amsterdam Pharma.

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →